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Short Report
Survival following the placement of gastrostomy
tube in patients with multiple sclerosis
Lisa Grandidge, Chayaporn Chotiyarnwong, Sean White, Jessica Denning and
Krishnan Padmakumari Sivaraman Nair
Abstract
Background: Around a third of people with multiple sclerosis (MS) experience dysphagia. There is a
need for disease-specific information on survival following placement of gastrostomy tube in people
with MS.
Objective: We aimed to study survival following gastrostomy in patients with MS.
Methods:We reviewed medical records, home enteral feeding database and death certificates of people
with MS who had gastrostomy from 2005 to 2017. Cox regression analysis was performed to identify
independent predictors associated with mortality after gastrostomy.
Results: Median survival of 53 patients with MS after gastrostomy was 21.73 months. Median duration
of hospital stay after gastrostomy was 14 days (IQR 5.25, 51.5). Survival at 30 days, 3 months, 1, 2, 5
and 10 years were 100% (53/53), 98.1% (52/53), 81.1% (43/53), 54.7% (29/53), 22.4% (11/49) and 6.8%
(3/44), respectively. Of 53 patients, 24 died due to respiratory tract infection. Patients who had gastro-
stomy tube before 50 years of age survived longer (median 28.48 months) compared with those who had
the gastrostomy after age 50 years (median 17.51 months) (p¼ 0.040).
Conclusion: Around 54% of patients with MS survived two or more years following gastrostomy.
Younger patients had better survival. The most frequent cause of death was respiratory infection.
Keywords: Multiple sclerosis, gastrostomy, enteral nutrition, deglutition disorders, survival rate, mor-
tality, dysphagia
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Introduction
Around a third of people with multiple sclerosis
(MS) experience dysphagia, which has a negative
impact on quality of life and increases the risk of
dehydration and aspiration.1,2 Insertion of a gastro-
stomy tube allows nutrition and hydration to be
administered safely in people with dysphagia.
Studies in motor neurone disease have identified
that patients find the decision to place a gastrostomy
tube a challenge, especially due to lack of disease-
specific information.3 There is a paucity of studies
describing the outcomes following placement of a
gastrostomy tube in patients with MS. This service
evaluation aims to describe outcomes for patients
with MS following placement of gastrostomy tube.
Materials and methods
Design
We performed a descriptive retrospective case note
review.
Participants
Patients diagnosed with MS who had a gastrostomy
placed for home enteral feeding (HEF) in Sheffield
from 2005 to 2017 were included. We reviewed all
patients with MS who had a gastrostomy tube place
between 2005 and 2017. The service evaluation was
approved by The Clinical Effectiveness Unit of
Sheffield Teaching Hospitals NHS Foundation
Trust (CEU Registration Number: 8300).
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Data collection
The data were retrieved from patients’ hospital med-
ical records, the local HEF team database and cer-
tificates of cause of death obtained from Her
Majesty’s General Register Office, Southport,
United Kingdom. We collected the following data:
indication for the gastrostomy tube placement,
Expanded Disability Status Scale (EDSS)4 function-
al score at the time of gastrostomy tube placement,
duration of hospital stay, discharge location, date of
death and cause of death.
Statistical analyses
Descriptive statistics were performed. Continuous
variables were reported using mean standard devi-
ation (SD) for normally distributed or median (Inter
Quartile Range (IQR) 25, IQR 75) for non-normally
distributed variables for Kolmogorov–Smirnov and
Shapiro–Wilk tests. Categorical variables are pre-
sented as number (percentage). Cumulative survival
probability was calculated using the Kaplan–Meier
method. Cox regression analysis was performed to
identify independent predictors associated with mor-
tality after gastrostomy placement. The results of the
regression analysis are represented with odds ratios
(ORs) and 95% confidence intervals (CIs).
Statistical analyses were performed using SSPS
Statistics version 18.0 (SPSS, Inc., Chicago, IL,
USA). A p-value <0.05 was considered to be statis-
tically significant.
Results
Fifty-three patients with MS had a gastrostomy tube
placed between 2005 and 2017. Baseline character-
istics of patients are shown in Table 1. On 31 July
2018, nine patients were alive. Median duration of
hospital stay after gastrostomy tube insertion was 14
(IQR 5.25, 51.5) days. Twenty-eight patients
(52.8%) were discharged back to their own home
and 25 patients (47.2%) to a nursing home.
Median survival time was 21.73 (IQR 12.54, 39.67)
months. Survival after gastrostomy is shown in
Table 1. Cause of death as recorded in the Medical
Certificates was respiratory tract infection (24), mul-
tiple sclerosis or frailty (14), osteomyelitis and pres-
sure sore (1), urinary tract infection (1), intestinal
obstruction (1), respiratory arrest following pro-
longed status epilepticus (1), asthma (1) and
unknown (1).
Patients who had gastrostomy tube before 50 years
of age survived longer (median 28.48 months) com-
pared with those who had the gastrostomy after age
50 years (median 17.51 months) (p¼ 0.040). Cox
regression analysis showed that age more than 50
years at gastrostomy tube insertion was a significant
predictor of shorter survival (OR 1.028) (1.001–
1.057, 95% CI) (p¼ 0.044) (Figure 1). The duration
of MS (p¼ 0.132), EDSS score (p¼ 0.647), type of
MS (p¼ 0.668), gender (p¼ 0.098), mobility
(p¼ 0.564), elective/emergency surgery (p¼ 0.841)
and location after discharge from hospital (p¼ 0.479)
did not predict survival after gastrostomy.
Discussion
This is the largest dataset on patients with MS on
gastrostomy tube for HEF. A retrospective study and
literature review about percutaneous endoscopic gas-
trostomy tube placement in neurodegenerative dis-
eases showed that there were no studies that focused
on the outcomes of patients with MS.5 Among 40
patients (13 with multiple sclerosis) the 30-day mor-
tality was 3/40 (8%). The 30-day mortality after the
gastrostomy placement in people with neurological
disease is between 0% and 28%.5 Survival of
patients with gastrostomy in our study at 30 days
was 100%. The 3 months, 1 and 2 year values
were also better than the survival reported in 500
patients with neurological disorders requiring gastro-
stomy. However, survival at 5 years in our study is
22.4%, which was less than the 32.2% reported in
this cohort.6
More than 80% of patients with MS survived more
than a year and more than 50% survived 2 years
after gastrostomy. HEF is likely to extend the sur-
vival of people with dysphagia due to MS. Most
frequent cause of death in our cohort was respiratory
tract infection, which was similar to a previous study
about mortality after gastrostomy in patients with
neurological dysphagia.7 While gastrostomy may
help meet patients’ nutritional requirements, it may
not prevent aspiration pneumonia. Previous studies
reported that older age was associated with poorer
outcome following gastrostomy.5,8,9 We also noted
that older age at the time of gastrostomy insertion
was a significant predictor of shorter survival. In
these studies the cut-off age for poor survival after
gastrostomy for neurogenic dysphagia was 75
years.5,8,9 Our data found that the cut-off age for
poor survival in patients with MS patient was 50
years. This could be because, unlike other neurode-
generative conditions causing dysphagia, MS is pre-
dominately a disease of young working-age adults.
This may help clinicians in their discussions with
patients with MS and their families about placement
of a gastrostomy tube for HEF.
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Limitations
This was a retrospective medical records review. We
did not evaluate patient-reported outcomes, the
challenges patients faced with HEF and impact on
quality of life. Around half (25/53) of our patients
were discharged to a care home. We did not look
Table 1. Clinical features, demographic characteristics and survival of people with MS who had a
gastrostomy.
Total (N¼ 53)
Age (years), meanSD 55.4 11.4
Sex, n (%)
- Male 16 (30.2%)
- Female 37 (69.8%)
Time from MS diagnosis to gastrostomy (years), meanSD 17.8 9.2
Type of multiple sclerosis, n (%)
- Relapsing–remitting MS 1 (1.9%)
- Primary progressive MS 5 (9.4%)
- Secondary progressive MS 46 (86.8%)
- Unknown 1 (1.9%)
EDSS score at time of gastrostomy, median (IQR), n (%) 8.5 (8,8.9)
- 6 1 (1.9%)
- 7 1 (1.9%)
- 7.5 5 (9.4%)
- 8 18 (34%)
- 8.5 14 (26.4%)
- 9 7 (13.2%)
- 9.5 6 (11.3%)
- Unknown 1 (1.9%)
Mobility status, n (%)
- Bed bound 22 (41.5%)
- Wheelchair bound 28 (52.8%)
- Mobile with gait aid 2 (3.8%)
- Unknown 1 (1.9%)
Indication for gastrostomy
- Swallowing difficulties 29 (54.7%)
- Aspiration pneumonia or recurrent pneumonia 14 (26.4%)
- Malnutrition or weight loss 5 (9.4%)
- Unsafe swallow 3 (5.7%)
- Prolonged intubation 1 (1.9%)
- Unknown 1 (1.9%)
Type of surgery
-Emergency 28 (52.8%)
-Elective 24 (45.3%)
-Unknown 1 (1.9%)
Location after discharge from hospital, n (%)
-Own home 28 (52.8%)
-Nursing home 25 (47.2%)
Survival after gastrostomy
30 day 53/53 (100%)
3 months 52/53 (98.1%)
12 months 43/53 (81.1%)
24 months 29/53 (54.7%)
60 months 11/49 (22.4%)
120 months 3/44 (6.8%)
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into the reason for discharge to care home. Our data
should not be interpreted as 50% of patients need
care home due to gastrostomy tube placement. The
goals of gastrostomy could be prevention of aspira-
tion, improve nutrition and hydration and improve
quality of life. The goal of gastrostomy was not
explicitly stated in the medical records or our data-
base. We also do not have data on people with MS
who refused gastrostomy. Our data do not answer
the question “Can gastrostomy extend survival,
improve nutrition and prevent aspiration in MS
patients who have indication for gastrostomy
insertion?” A prospective study, with patients who
refuse gastrostomy as control, may be helpful in
answering these important questions.
Conclusion
Patients with MS survive 2 years and longer after
placement of gastrostomy tube for HEF. The most
common cause of death was respiratory infection.
This information will help inform clinicians and
patients with MS making decisions regarding gastro-
stomy tube placement. Further prospective research
is required to evaluate the outcomes of patients with
MS on HEF, particularly as the condition progresses.
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Figure 1. Cox regression analysis comparing survival
after gastrostomy for patients with MS of age more than
50 years and 50 years or less.
Y axis: Cumulative survival; X axis: Number of years after
gastrostomy.
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